Global Multiple Sclerosis (MS) Market – Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)
Executive Summary
The Global Multiple Sclerosis Market is estimated at USD 26.01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market. Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.
The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).
The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.
Scope of the Report
The Global Multiple Sclerosis Market is estimated at USD 26.01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market. Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.
The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).
The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.
Scope of the Report
- The report analyses the Multiple Sclerosis Market for the historical period 2016-2020 and the forecast period of 2021-2026.
- The report analyses the Multiple Sclerosis Market by Value (USD Million).
- The report analyses the Multiple Sclerosis Market Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others).
- The report analyses the Multiple Sclerosis Market by Route of Administration (Oral, Injectable, Intravenous).
- The report analyses the Multiple Sclerosis Market Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
- The Global The report analyses the Multiple Sclerosis Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
- Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).
- The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Drug Class, by Route of Administration, by Distribution Channel.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, Pipelines and new product development. The companies analysed in the report include Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Pfizer Inc., GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Limited, BAYER AG, Biogen, EMD Sereno, NervGen Pharma.
- Healthcare and Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
1. REPORT SCOPE AND METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. MULTIPLE SCLEROSIS MARKET: PRODUCT OUTLOOK
4. GLOBAL MULTIPLE SCLEROSIS MARKET: SIZING AND FORECAST
4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Multiple Sclerosis Market
5. GLOBAL MULTIPLE SCLEROSIS MARKET SEGMENTATION - BY DRUG CLASS, BY ROUTE OF ADMINISTRATION, BY DISTRIBUTION CHANNEL
5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class
5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)
5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)
5.1.3 Interferons - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration
5.2.1 Oral - Market Size and Forecast (2016-2026)
5.2.2 Injectable - Market Size and Forecast (2016-2026)
5.2.3 Intravenous - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel
5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)
5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)
5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)
6. GLOBAL MULTIPLE SCLEROSIS MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region
7. NORTH AMERICA MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)
7.2 North America Multiple Sclerosis Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.6 North America Multiple Sclerosis Market: Country Analysis
7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country
7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8. EUROPE MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)
8.2 Europe Multiple Sclerosis Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.6 Europe Multiple Sclerosis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country
8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9. ASIA PACIFIC MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis
9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country
9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
911 JAPAN MULTIPLE SCLEROSIS MARKET: SIZE AND FORECAST (2016-2026), BY VALUE
9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
10. GLOBAL MULTIPLE SCLEROSIS MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026
11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Product Pipeline of Leading Multiple Sclerosis Companies
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Bristol-Myers Squibb
13.2 F. Hoffman-La Roche, Ltd.
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Teva Pharmaceuticals Industries Limited
13.7 BAYER AG
13.8 Biogen
13.9 EMD Sereno
13.10 NervGen Pharma
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. MULTIPLE SCLEROSIS MARKET: PRODUCT OUTLOOK
4. GLOBAL MULTIPLE SCLEROSIS MARKET: SIZING AND FORECAST
4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Multiple Sclerosis Market
5. GLOBAL MULTIPLE SCLEROSIS MARKET SEGMENTATION - BY DRUG CLASS, BY ROUTE OF ADMINISTRATION, BY DISTRIBUTION CHANNEL
5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class
5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)
5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)
5.1.3 Interferons - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration
5.2.1 Oral - Market Size and Forecast (2016-2026)
5.2.2 Injectable - Market Size and Forecast (2016-2026)
5.2.3 Intravenous - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel
5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)
5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)
5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)
6. GLOBAL MULTIPLE SCLEROSIS MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region
7. NORTH AMERICA MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)
7.2 North America Multiple Sclerosis Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.6 North America Multiple Sclerosis Market: Country Analysis
7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country
7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8. EUROPE MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)
8.2 Europe Multiple Sclerosis Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.6 Europe Multiple Sclerosis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country
8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9. ASIA PACIFIC MULTIPLE SCLEROSIS MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis
9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country
9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
911 JAPAN MULTIPLE SCLEROSIS MARKET: SIZE AND FORECAST (2016-2026), BY VALUE
9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
10. GLOBAL MULTIPLE SCLEROSIS MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026
11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Product Pipeline of Leading Multiple Sclerosis Companies
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Bristol-Myers Squibb
13.2 F. Hoffman-La Roche, Ltd.
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Teva Pharmaceuticals Industries Limited
13.7 BAYER AG
13.8 Biogen
13.9 EMD Sereno
13.10 NervGen Pharma
TABLES AND FIGURES
Figure 1: Global Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global Multiple Sclerosis Market- By Drug Class Market Share, 2020 & 2026
Figure 8: Global Multiple Sclerosis Market- By Immunomodulators, By Value (USD Million), 2016-2026
Figure 9: Global Multiple Sclerosis Market- By Immunosuppressants, By Value (USD Million), 2016-2026
Figure 10: Global Multiple Sclerosis Market- By Interferons, By Value (USD Million), 2016-2026
Figure 11: Global Multiple Sclerosis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Multiple Sclerosis Market- By Route of Administration Market Share, 2020 & 2026
Figure 13: Global Multiple Sclerosis Market- By Oral, By Value (USD Million), 2016-2026
Figure 14: Global Multiple Sclerosis Market- By Injectable, By Value (USD Million), 2016-2026
Figure 15: Global Multiple Sclerosis Market- By Intravenous, By Value (USD Million), 2016-2026
Figure 16: Global Multiple Sclerosis Market- By Distribution Channel Market Share, 2020 & 2026
Figure 17: Global Multiple Sclerosis Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026
Figure 18: Global Multiple Sclerosis Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
Figure 19: Global Multiple Sclerosis Market- By Online Pharmacy, By Value (USD Million), 2016-2026
Figure 20: Global Multiple Sclerosis Market- By Region Market Share, 2020 & 2026
Figure 21: North America Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 22: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 24: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 25: North America Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 26: North America Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 27: North America Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 28: Market Opportunity Chart of North America Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 29: North America Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 30: United States Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 31: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 32: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 33: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 34: United States Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 35: United States Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 36: United States Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 37: Canada Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 38: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 40: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 41: Canada Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 42: Canada Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 43: Canada Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 44: Europe Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 45: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 46: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 47: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 48: Europe Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 49: Europe Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 50: Europe Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 51: Market Opportunity Chart of Europe Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 52: Europe Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 53: Germany Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 54: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 55: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 56: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 57: Germany Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 58: Germany Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 59: Germany Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 60: United Kingdom Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 61: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 62: United Kingdom Number of people with MS (per 100,000 people), 2017
Figure 63: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 64: United Kingdom Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 65: United Kingdom Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 67: France Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 68: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 69: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 70: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 71: France Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 72: France Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 73: France Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 74: Italy Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 75: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 76: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 77: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 78: Italy Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 79: Italy Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 80: Italy Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 81: Asia Pacific Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 82: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 83: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 84: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 85: Asia Pacific Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 86: Asia Pacific Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 87: Asia Pacific Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 88: Market Opportunity Chart of APAC Multiple Sclerosis Market- By Country, By Value (Year-2026)
Figure 89: APAC Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 90: China Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 91: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 92: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 93: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 94: China Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 95: China Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 96: China Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 97: Japan Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 98: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 99: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 100: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 101: Japan Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 102: Japan Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 103: Japan Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 104: India Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 105: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 106: e-pharmacy market in India (USD million)
Figure 107: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 108: India Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 109: India Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 110: India Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 111: South Korea Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 112: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 113: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 114: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 115: South Korea Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 116: South Korea Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 117: South Korea Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 118: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Drug Class (Year-2016-2026)
Figure 119: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Route of Administration (Year 2016-2026)
Figure 120: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Distribution Channel (Year 2016-2026)
Figure 121: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Region (Year 2016-2026)
Figure 122: Global Multiple Sclerosis company market share (%), 2020
Figure 123: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 124: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 125: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 126: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 127: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 128: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 129: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 130: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 131: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 132: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 133: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 134: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 135: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 136: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 137: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 138: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 139: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 140: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 141: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 142: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 143: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
Figure 144: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
Figure 145: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 146: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 147: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 148: Bayer Group, By Business Segment (%), FY2020
Figure 149: Bayer Group, By Geographical Segment (%), FY2020
Figure 150: Biogen Sales Revenues, 2016-2020 (USD Million)
Figure 151: Biogen Net Profit, 2016-2020 (USD Million)
Figure 152: Biogen, By Business Segment (%), FY2020
Figure 153: Biogen, By Geographical Segment (%), FY2020
Table A Product Pipeline of Leading Multiple Sclerosis Companies
Table B Product Pipeline of Leading Multiple Sclerosis Companies
Table C Product Pipeline of Leading Multiple Sclerosis Companies - NervGen Pharma
Figure 1: Global Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global Multiple Sclerosis Market- By Drug Class Market Share, 2020 & 2026
Figure 8: Global Multiple Sclerosis Market- By Immunomodulators, By Value (USD Million), 2016-2026
Figure 9: Global Multiple Sclerosis Market- By Immunosuppressants, By Value (USD Million), 2016-2026
Figure 10: Global Multiple Sclerosis Market- By Interferons, By Value (USD Million), 2016-2026
Figure 11: Global Multiple Sclerosis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Multiple Sclerosis Market- By Route of Administration Market Share, 2020 & 2026
Figure 13: Global Multiple Sclerosis Market- By Oral, By Value (USD Million), 2016-2026
Figure 14: Global Multiple Sclerosis Market- By Injectable, By Value (USD Million), 2016-2026
Figure 15: Global Multiple Sclerosis Market- By Intravenous, By Value (USD Million), 2016-2026
Figure 16: Global Multiple Sclerosis Market- By Distribution Channel Market Share, 2020 & 2026
Figure 17: Global Multiple Sclerosis Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026
Figure 18: Global Multiple Sclerosis Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
Figure 19: Global Multiple Sclerosis Market- By Online Pharmacy, By Value (USD Million), 2016-2026
Figure 20: Global Multiple Sclerosis Market- By Region Market Share, 2020 & 2026
Figure 21: North America Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 22: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 24: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 25: North America Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 26: North America Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 27: North America Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 28: Market Opportunity Chart of North America Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 29: North America Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 30: United States Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 31: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 32: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 33: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 34: United States Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 35: United States Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 36: United States Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 37: Canada Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 38: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 40: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 41: Canada Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 42: Canada Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 43: Canada Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 44: Europe Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 45: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 46: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 47: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 48: Europe Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 49: Europe Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 50: Europe Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 51: Market Opportunity Chart of Europe Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 52: Europe Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 53: Germany Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 54: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 55: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 56: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 57: Germany Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 58: Germany Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 59: Germany Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 60: United Kingdom Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 61: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 62: United Kingdom Number of people with MS (per 100,000 people), 2017
Figure 63: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 64: United Kingdom Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 65: United Kingdom Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 67: France Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 68: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 69: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 70: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 71: France Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 72: France Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 73: France Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 74: Italy Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 75: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 76: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 77: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 78: Italy Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 79: Italy Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 80: Italy Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 81: Asia Pacific Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 82: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 83: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 84: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 85: Asia Pacific Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 86: Asia Pacific Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 87: Asia Pacific Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 88: Market Opportunity Chart of APAC Multiple Sclerosis Market- By Country, By Value (Year-2026)
Figure 89: APAC Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 90: China Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 91: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 92: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 93: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 94: China Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 95: China Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 96: China Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 97: Japan Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 98: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 99: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 100: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 101: Japan Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 102: Japan Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 103: Japan Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 104: India Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 105: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 106: e-pharmacy market in India (USD million)
Figure 107: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 108: India Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 109: India Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 110: India Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 111: South Korea Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 112: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 113: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 114: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 115: South Korea Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 116: South Korea Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 117: South Korea Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 118: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Drug Class (Year-2016-2026)
Figure 119: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Route of Administration (Year 2016-2026)
Figure 120: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Distribution Channel (Year 2016-2026)
Figure 121: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Region (Year 2016-2026)
Figure 122: Global Multiple Sclerosis company market share (%), 2020
Figure 123: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 124: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 125: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 126: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 127: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 128: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 129: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 130: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 131: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 132: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 133: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 134: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 135: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 136: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 137: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 138: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 139: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 140: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 141: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 142: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 143: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
Figure 144: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
Figure 145: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 146: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 147: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 148: Bayer Group, By Business Segment (%), FY2020
Figure 149: Bayer Group, By Geographical Segment (%), FY2020
Figure 150: Biogen Sales Revenues, 2016-2020 (USD Million)
Figure 151: Biogen Net Profit, 2016-2020 (USD Million)
Figure 152: Biogen, By Business Segment (%), FY2020
Figure 153: Biogen, By Geographical Segment (%), FY2020
Table A Product Pipeline of Leading Multiple Sclerosis Companies
Table B Product Pipeline of Leading Multiple Sclerosis Companies
Table C Product Pipeline of Leading Multiple Sclerosis Companies - NervGen Pharma
